Arecor Announces Presentation at EASD 2022 of Phase I Clinical Trial of At278 Ultra-concentrated Ultra-rapid Acting Insulin for Diabetes
Cambridge, UK – Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled “Phase I study investigating PK and PD of highly-concentrated insulin aspart AT278 U500” has been selected for presentation as part of the Short Oral Discussion Session A at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) meeting, which will be held from 19-23 September 2022 in Stockholm, Sweden and online.
The presentation will take place on Tuesday 20 September during the SO 19 Short Oral Discussion Session “How complicated is type 1 diabetes?” (11:45-12:45)
Oral Presentation: Phase I study investigating PK and PD of highly-concentrated insulin aspart AT278 U500
Presenting Author: Dr Eva Svehlikova
Presentation Number: 407
Tuesday, 20 September 2022, between 11:45 and 12:45 (Central European Time)
AT278 is an ultra-concentrated (500U/mL) novel formulation of insulin that has been designed to significantly accelerate insulin absorption post injection to enable more effective and convenient management of blood glucose levels in people with high daily insulin requirements.
Sarah Howell, Chief Executive Officer at Arecor, said:
“AT278 has the potential to be the first, and potentially only, ultra-concentrated (500U/mL) yet ultra-rapid acting insulin. This product offers the potential to significantly improve post prandial control whilst also reducing the injection volume and number of daily injections for the growing population of people living with diabetes who have high daily insulin needs, particularly those with type 2 diabetes. In addition, with its unique profile, AT278 is a key enabler in the development of next generation miniaturised insulin delivery devices, an expected future disrupter in the market. We look forward to sharing our ground-breaking data for this next generation insulin candidate with scientific colleagues in Stockholm and around the world.”
